Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients
Introduction: Pelvic hypoperfusion caused by atherosclerosis has been proposed as a cause of lower urinary tract dysfunction including overactive bladder syndrome (OAB). Limited data indicate that OAB patients with concomitant diabetes or hypertension, known risk factors of atherosclerosis, may exhi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1144470/full |
| _version_ | 1797856380617490432 |
|---|---|
| author | A. Elif Müderrisoglu Ayse A. Sakul Sandra Murgas Jean J. M. C. H. de la Rosette Martin C. Michel |
| author_facet | A. Elif Müderrisoglu Ayse A. Sakul Sandra Murgas Jean J. M. C. H. de la Rosette Martin C. Michel |
| author_sort | A. Elif Müderrisoglu |
| collection | DOAJ |
| description | Introduction: Pelvic hypoperfusion caused by atherosclerosis has been proposed as a cause of lower urinary tract dysfunction including overactive bladder syndrome (OAB). Limited data indicate that OAB patients with concomitant diabetes or hypertension, known risk factors of atherosclerosis, may exhibit greater baseline OAB symptoms and slightly smaller therapeutic responses to treatment, but the impact of a combined presence of diabetes and hypertension has not been reported. Therefore, we have explored whether the combined presence of both comorbidities is associated with greater baseline OAB symptoms than that of either comorbidity alone. Secondary questions were exploration of the impact of either comorbidity on baseline symptoms, and of the impact of either comorbidity alone and their combination on therapeutic responses.Methods: Data from two non-interventional studies applying treatment with propiverine ER 30 or 45 mg/d for 12 weeks were analyzed.Results: Number of urgency episodes in the combination group was greater than with each comorbidity alone. The impact of comorbidities on baseline intensity of incontinence, frequency or nocturia or Patient Perception of Bladder Condition was less consistent or absent. Either comorbidity alone was associated with a smaller % improvement of symptoms, and their combination had a greater effect than either alone. However, all attenuations associated with comorbidity were small relative to the overall improvement. Conclusions: We conclude that comorbidities of diabetes and hypertension have detectable effects on OAB symptoms and treatment responses, but the small magnitude of these alterations does not justify changing existing paradigms for the clinical management of OAB. |
| first_indexed | 2024-04-09T20:40:32Z |
| format | Article |
| id | doaj.art-ce18b18f2595418fa7fee7a0179f06cb |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-09T20:40:32Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-ce18b18f2595418fa7fee7a0179f06cb2023-03-30T05:30:32ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-03-011410.3389/fphar.2023.11444701144470Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patientsA. Elif Müderrisoglu0Ayse A. Sakul1Sandra Murgas2Jean J. M. C. H. de la Rosette3Martin C. Michel4Department of Medical Pharmacology, Istanbul Medipol University, Istanbul, TürkiyeDepartment of Medical Pharmacology, Istanbul Medipol University, Istanbul, TürkiyeAPOGEPHA Arzneimittel GmbH, Dresden, GermanyDepartment of Urology, Medipol Mega University Hospital, Istanbul Medipol University, Istanbul, TürkiyeDepartment of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, GermanyIntroduction: Pelvic hypoperfusion caused by atherosclerosis has been proposed as a cause of lower urinary tract dysfunction including overactive bladder syndrome (OAB). Limited data indicate that OAB patients with concomitant diabetes or hypertension, known risk factors of atherosclerosis, may exhibit greater baseline OAB symptoms and slightly smaller therapeutic responses to treatment, but the impact of a combined presence of diabetes and hypertension has not been reported. Therefore, we have explored whether the combined presence of both comorbidities is associated with greater baseline OAB symptoms than that of either comorbidity alone. Secondary questions were exploration of the impact of either comorbidity on baseline symptoms, and of the impact of either comorbidity alone and their combination on therapeutic responses.Methods: Data from two non-interventional studies applying treatment with propiverine ER 30 or 45 mg/d for 12 weeks were analyzed.Results: Number of urgency episodes in the combination group was greater than with each comorbidity alone. The impact of comorbidities on baseline intensity of incontinence, frequency or nocturia or Patient Perception of Bladder Condition was less consistent or absent. Either comorbidity alone was associated with a smaller % improvement of symptoms, and their combination had a greater effect than either alone. However, all attenuations associated with comorbidity were small relative to the overall improvement. Conclusions: We conclude that comorbidities of diabetes and hypertension have detectable effects on OAB symptoms and treatment responses, but the small magnitude of these alterations does not justify changing existing paradigms for the clinical management of OAB.https://www.frontiersin.org/articles/10.3389/fphar.2023.1144470/fulloveractive bladder syndromediabeteshypertensioncomorbiditypropiverinetreatment |
| spellingShingle | A. Elif Müderrisoglu Ayse A. Sakul Sandra Murgas Jean J. M. C. H. de la Rosette Martin C. Michel Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients Frontiers in Pharmacology overactive bladder syndrome diabetes hypertension comorbidity propiverine treatment |
| title | Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients |
| title_full | Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients |
| title_fullStr | Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients |
| title_full_unstemmed | Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients |
| title_short | Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients |
| title_sort | association of diabetes hypertension and their combination with basal symptoms and treatment responses in overactive bladder patients |
| topic | overactive bladder syndrome diabetes hypertension comorbidity propiverine treatment |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1144470/full |
| work_keys_str_mv | AT aelifmuderrisoglu associationofdiabeteshypertensionandtheircombinationwithbasalsymptomsandtreatmentresponsesinoveractivebladderpatients AT ayseasakul associationofdiabeteshypertensionandtheircombinationwithbasalsymptomsandtreatmentresponsesinoveractivebladderpatients AT sandramurgas associationofdiabeteshypertensionandtheircombinationwithbasalsymptomsandtreatmentresponsesinoveractivebladderpatients AT jeanjmchdelarosette associationofdiabeteshypertensionandtheircombinationwithbasalsymptomsandtreatmentresponsesinoveractivebladderpatients AT martincmichel associationofdiabeteshypertensionandtheircombinationwithbasalsymptomsandtreatmentresponsesinoveractivebladderpatients |